Comparison of the Ability of Various Pharmaceutical Silicates to Amorphize and Enhance Dissolution of Indomethacin Upon Co-grinding

REFERENCES

• Kinoshita K, Baba A, Nagayasu K, et al. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J. Pharm. Sci. 2002; 91: 362–370
   PubMed Web of Science ®Google Scholar
• Law D, Schmitt EA, Marsh KC, et al. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J. Pharm. Sci. 2004; 93: 563–570
   PubMed Web of Science ®Google Scholar
• Yonemochi E, Kitahara S, Maeda S, Yamamura S, Oguchi T, Yamamoto K. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur. J. Pharm. Sci. 1999; 7: 331–338
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int. J. Pharm. 2005; 293: 155–164
   PubMed Web of Science ®Google Scholar
• Tong P, Zografi G. A study of amorphous molecular dispersions of indomethacin and its sodium salt. J. Pharm. Sci. 2001; 90: 1991–2004
   PubMed Web of Science ®Google Scholar
• Tong P, Zografi G. Solid-state characteristics of amorphous sodium indomethacin relative to its free acid. Pharm. Res. 1999; 16: 1186–1192
   PubMed Web of Science ®Google Scholar
• Yang KY, Glemza R, Jarowski CI. Effects of amorphous silicon dioxides on drug dissolution. J. Pharm. Sci. 1979; 68: 560–565
   PubMed Web of Science ®Google Scholar
• Monkhouse DC, Lach JL. Use of adsorbents in enhancement of drug dissolution. I. J. Pharm. Sci. 1972; 61: 1430–1435
   PubMed Web of Science ®Google Scholar
• Kim KH, Frank MJ, Henderson NL. Application of differential scanning calorimetry to the study of solid drug dispersions. J. Pharm. Sci. 1985; 74: 283–289
   PubMed Web of Science ®Google Scholar
• Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997; 86: 1–12
   PubMed Web of Science ®Google Scholar
• Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm. Res. 2000; 17: 397–404
   PubMed Web of Science ®Google Scholar
• Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M. Stability of amorphous indomethacin compounded with silica. Int. J. Pharm. 2001; 226: 81–91
   PubMed Web of Science ®Google Scholar
• Gupta MK, Vanwert A, Bogner RH. Formation of physically stable amorphous drugs by milling with neusilin. J. Pharm. Sci. 2003; 92: 536–551
   PubMed Web of Science ®Google Scholar
• Bahl D, Bogner RH. Amorphization of indomethacin by co-grinding with Neusilin US2: amorphization kinetics, physical stability and mechanism. Pharm. Res. 2006; 23: 2317–2325
   PubMed Web of Science ®Google Scholar
• Fuji C. Company literature on Neusilin. Fuji Chemical Industries, ToyamaJapan 1997
   Google Scholar
• Chuang IS, Maciel GE. Probing hydrogen bonding and the local environment of silanols on silica surfaces via nuclear spin cross polarization dynamics. J. Am. Chem. Soc. 1996; 118: 401–406
   Web of Science ®Google Scholar
• Chuang IS, Maciel GE. A detailed model of local structure and silanol hydrogen bonding of silica gel surfaces. J. Phys. Chem. B. 1997; 101: 3052–3064
   Web of Science ®Google Scholar
• Watanabe T, Ohno I, Wakiyama N, Kusai A, Senna M. Controlled dissolution properties of indomethacin by compounding with silica. S.T.P. Pharma Sciences. 2002; 12: 363–367
   Google Scholar
• Kinoshita M, Baba K, Nagayasu A, et al. Highly stabilized amorphous 3-bis(4-methoxyphenyl)methylene-2-indolinone (TAS-301) in melt-adsorbed products with silicate compounds. Drug Dev. Ind. Pharm. 2003; 29: 523–529
   PubMed Web of Science ®Google Scholar
• Bahl D, Bogner RH. Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: the case of indomethacin. AAPS PharmSciTech. 2008; 9: 146–153
   PubMed Web of Science ®Google Scholar
• PJ SinkoMartin's Physical Pharmacy and Pharmaceutical Sciences5^th, . Lippincott Williams and Williams, Philadelphia 2006; 213–214
   Google Scholar
• Barrett EP, Joyner LG, Halenda PP. The determination of pore volume and area distributions in porous substances. I. Computations from nitrogen isotherms. J. Am. Chem. Soc. 1951; 73: 373–380
   Web of Science ®Google Scholar
• Eddaoudi M. S Lowell, JE Shields, MA Thomas, M ThommesCharacterization of Porous Solids and Powders: Surface Area, Pore Size and Density, , 2005
   Google Scholar
• Horvath G, Kawazoe K. Method for the calculation of effective pore size distribution in molecular sieve carbon. Journal of Chemical Engineering of Japan. 1983; 16: 470–475
   Web of Science ®Google Scholar
• Palmeri A. RC Rowe, PJ Sheskey, PJ WellerHandbook of Pharmaceutical Excipients4^th, . Pharmaceutical Press; Washington: American Pharmaceutical Association, London 1994; 343–346
   Google Scholar
• Konno T, Kinuno K, Kataoka K. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. I. Effect of vapor pressure of the medicinals on changes in crystalline properties. Chem Pharm. Bull. 1986; 34: 301–307
   PubMed Web of Science ®Google Scholar
• Oguchi T, Tozuka Y, Okonogi S, Yonemochi E, Yamamoto K. Improved dissolution of naproxen from solid dispersions with porous additives. Yakuzaigaku. 1997; 57: 168–173
   Google Scholar
• Enustun BV, Senturk HS, Yurdakul O. Capillary freezing and melting. J. Colloid Interface Sci. 1978; 65: 509–516
   Web of Science ®Google Scholar
• Faroongsarng D, Peck GE. Thermal porosity analysis of croscarmellose sodium and sodium starch glycolate by differential scanning calorimetry. AAPS PharmSciTech. 2003; 4(4)E67
   Google Scholar
• Valckenborg RME, Pel L, Kopinga K. Combined NMR cryoporometry and relaxometry. J. Phys. D. Appl. Phys. 2002; 35: 249–256
   Google Scholar